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Abstract
Background: Several prognostic signatures for early oestrogen receptor-positive (ER+) breast cancer have been
established with a 10-year follow-up. We tested the hypothesis that signatures optimised for 0–5-year and 5–10-
year follow-up separately are more prognostic than a single signature optimised for 10 years.
Methods: Genes previously identified as prognostic or associated with endocrine resistance were tested in publicly
available microarray data set using Cox regression of 747 ER+/HER2− samples from post-menopausal patients
treated with 5 years of endocrine therapy. RNA expression of the selected genes was assayed in primary ER+/HER2
− tumours from 948 post-menopausal patients treated with 5 years of anastrozole or tamoxifen in the TransATAC
cohort. Prognostic signatures for 0–10, 0–5 and 5–10 years were derived using a penalised Cox regression (elastic
net). Signature comparison was performed with likelihood ratio statistics. Validation was done by a case-control
(POLAR) study in 422 samples derived from a cohort of 1449.
Results: Ninety-three genes were selected by the modelling of microarray data; 63 of these were significantly
prognostic in TransATAC, most similarly across each time period. Contrary to our hypothesis, the derived early and
late signatures were not significantly more prognostic than the 18-gene 10-year signature. The 18-gene 10-year
signature was internally validated in the TransATAC validation set, showing prognostic information similar to that of
Oncotype DX Recurrence Score, PAM50 risk of recurrence score, Breast Cancer Index and IHC4 (score based on four
IHC markers), as well as in the external POLAR case-control set.
Conclusions: The derived 10-year signature predicts risk of metastasis in patients with ER+/HER2− breast cancer
similar to commercial signatures. The hypothesis that early and late prognostic signatures are significantly more
informative than a single signature was rejected.
Keywords: Breast cancer, Oestrogen receptor, Prognostic tests, Biomarkers, Late recurrence
Background
Five years of adjuvant endocrine therapy is standard treat-
ment for patients with primary oestrogen receptor-positive
(ER+) breast cancer, and it clearly improves prognosis [1].
Multiparametric molecular assays are increasingly used to
estimate prognosis and guide treatment decisions of
patients with primary ER+ breast cancer. These include the
Oncotype DX (OncotypeIQ/Genomic Health, Inc., Red-
wood City, CA, USA) Recurrence Score (RS) [2], Prosigna
PAM50 (NanoString Technologies, Seattle, WA, USA) [3],
Breast Cancer Index (BCI) [4], EndoPredict (Myriad Genet-
ics, Zurich, Switzerland) [5] and IHC4 [6]. All of them have
been evaluated in the TransATAC series of samples that
were established from patients with ER+ primary breast
cancer randomised to treatment with 5 years of anastrozole
or tamoxifen in the ATAC (Arimidex, Tamoxifen, Alone or
in Combination) trial [7]. It has become clear that, follow-
ing surgery, the risk of recurrence in ER+ primary breast
cancer is not constant, which is underlined by molecular
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differences. In TransATAC we have previously shown that
the oestrogen module of RS was prognostic within 5 years
of surgery (during endocrine therapy), however it became
non-informative for recurrences beyond 5 years, thus weak-
ening the overall prognostic value of RS [8]. In the same
data set, patients with high ER expression by RT-PCR were
twice as likely to have a relapse 5–10 years after surgery
than within the first 5 years. Bianchini et al. reported risk
stratification by integrating the mitotic kinase score (MKS)
and an oestrogen receptor-related score (ERS), both based
on genes constituting the proliferation and oestrogen mod-
ules of RS. Women with high MKS and ERS tumours were
at greater risk of late recurrence [9]. More recently, im-
proved risk estimation beyond 5 years by RS was reported
when integrated with dichotomised ER expression assessed
by RT-PCR [10].
Extending endocrine therapy beyond 5 years has been
shown to reduce late-recurrence rate [11, 12], however
those most likely to benefit from such therapy need to be
identified. Although some of the widely used prognostic
assays for ER+ patients have been shown to be prognostic
for risk beyond 5 years [13–16], none of them have been
optimised to quantify residual risk after 5 years free from
recurrence, and their ability to predict late relapse varies
substantially [17]. The different time-dependent perform-
ance of multiparametric molecular signatures indicates
that molecular features of ER+ breast cancers may be
identified to improve prediction of residual risk in order
to spare those patients with significantly low risk of late
recurrence from extended endocrine therapy.
We therefore hypothesised that prognostic signatures
optimised specifically for the early (0–5 years) and late (5–
10 years) follow-up periods, respectively, would be more
prognostic than a single signature optimised for the whole
10-year follow-up period. To test this hypothesis, we devel-
oped time-dependent prognostic signatures in patient sam-
ples from the TransATAC series for early, late and 10-year
follow-up periods. The prognostic performance was tested
in an independent sample set and against commercial
signatures already assessed in TransATAC. Our primary
aim was to compare the prognostic value of the newly
developed signature(s) added to Clinical Treatment Score
(CTS) [6] with that of PAM50 risk of recurrence (ROR)
based on subtype and proliferation added to CTS.
Methods
Patient cohorts
Our initial analysis drew from four published breast can-
cer cohorts (GSE6532, GSE9195, GSE17705, GSE26971)
analysed on either of the Affymetrix Human Genome
HG-U133A (GPL96) and HG-U133 Plus 2.0 (GPL570)
microarray platforms (Affymetrix, Santa Clara, CA,
USA). The two platforms shared 22,277 probes to which
we restricted our analyses. This cohort had 747 unique
patient samples that matched our selection criteria: ER+,
HER2−, treated with 5 years of endocrine therapy,
chemotherapy-naive, with information on either distant
metastasis-free survival (DMFS) or relapse-free survival
(RFS) available with a long follow-up. Details of the
inclusion criteria are listed in Additional file 1: Methods,
and a full list of samples included in the analysis is
shown in Additional file 2: Table S1.
In the TransATAC cohort, RNA was available from 948
formalin-fixed, paraffin-embedded (FFPE) tumours from the
ATAC trial, previously extracted by Genomic Health Inc.
(GHI) [18]. Eligibility required hormone receptor-positive/
HER2− disease, without chemotherapy treatment and at
least 500 ng of RNA available. One hundred eighty-three
recurrence events were recorded for this cohort. This study
was approved by the South-East London Research Ethics
Committee, and all patients gave informed consent.
The POLAR (Predictors Of early versus LAte Recur-
rence in ER+ breast cancer) samples were identified
from archives of Royal Marsden Hospital (RMH),
London, UK, and Lund University Hospital Biobank,
Lund, Sweden. Eligibility criteria were patients with ER
+/HER2− early breast cancer diagnosed between January
2000 and December 2004, treated with curative intent
and with a follow-up data cut-off at May 2014. Patients
must have received 5 years of adjuvant endocrine
therapy (unless relapse occurred within this time); (neo)-
adjuvant chemotherapy was permitted. A 422-sample
case-control design was used; control subjects were
randomly selected according to matching criteria from
among the remaining cohort of patients who did not
relapse during follow-up. The total number of patients
drawn upon was 1449. The following four matching
criteria were used in this study: (1) age at diagnosis (< 50
or > 50 years), (2) Nottingham Prognostic Index (NPI)
category (< 3.4, 3.4–5.4, > 5.4), (3) type of adjuvant
endocrine therapy (tamoxifen only vs. any aromatase
inhibitor [AI]) and (4) chemotherapy use (yes or no).
Two-hundred forty-seven recurrence events were
recorded. The POLAR study was approved by the RMH
Research Ethics Committee (CCR 4122) and the ethics
committee of Lund University Hospital (LU 240-01).
Study endpoints
The primary endpoint was time to any recurrence, which
was defined as locoregional (ipsilateral breast, contralateral
breast and regional lymph nodes) and/or distant recur-
rence. Secondary endpoint was time to distant recurrence,
which was the time from diagnosis until metastasis from
the primary tumour at distant organs, excluding contralat-
eral disease and locoregional and ipsilateral recurrences.
Death before recurrence was treated as a censoring event
for both endpoints.
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Analytic procedures
In the microarray data set, 454 probes representing 454
genes (Additional file 2: Table S3) were analysed at univar-
iate level; those significant in univariate analyses in a par-
ticular setting were entered into multivariable analyses.
Further details are provided in Additional file 1: Methods.
For TransATAC, RNA was extracted by GHI for the RS
study [18]. RNA (100 ng) was used with the nCounter
platform (NanoString Technologies) to assay the 93
endogenous and 7 reference genes selected in the process
of the microarray expression analysis in 948 TransATAC
samples.
For POLAR, RNA was extracted from three 3 × 10-μm
unstained sections with more than 40% tumour cellularity
using the RNeasy FFPE kit (Qiagen, Hilden, Germany) ac-
cording to the manufacturer’s instructions. RNA was quan-
tified by using a NanoDrop instrument (Thermo Fisher
Scientific, Wilmington, DE, USA). Between 50 and 200 ng
of RNA was used to profile the expression of 27 endogen-
ous and 5 reference genes with the NanoString nCounter.
NanoString expression data were background-corrected
by subtracting the mean of the eight negative control
probes, normalised with the geometric mean of five refer-
ence genes that had a correlation of Pearson’s r > 0.8 with
all endogenous genes. The data set was then logarithmic-
ally (base 2) transformed and z-score-transformed. The
KIF20A gene was detected in < 10% of samples in the
TransATAC cohort and was removed from the data set.
CTS, which carries information on tumour size, nodal
status, grade, age and type of endocrine therapy, was cal-
culated as published previously [6].
We trained separate early, late and 10-year signatures by
performing elastic net analysis in the TransATAC training
cohort. Our objective was to test if the early and late
signatures had statistically significantly more prognostic
power than the 10-year signature. If so, we would test the
validity of the early and late signatures in the
non-chemotherapy-treated subpopulation of POLAR and
also test their performance in the chemotherapy-treated
POLAR cohort. If the early and late signatures were not
statistically significantly more prognostic than the overall
signature, we would test the validity of the overall
signature in the chemotherapy-naive POLAR group and
explore its performance in the chemotherapy-treated
POLAR group.
Statistical analyses of the cohort with microarray data
were carried out at the Institute of Cancer Research (ICR)
using R version 3.03 software (R Foundation for Statistical
Computing, Vienna, Austria). Statistical analyses using the
TransATAC cohort were performed at Queen Mary
University of London with STATA version 13.1 (Stata-
Corp, College Station, TX, USA) and R version 3.0.3 soft-
ware. Statistical work on POLAR was carried out at RMH
using the Statistical Analysis Plan version 2.0 and Prism
6.0c (GraphPad Software, La Jolla, CA, USA) software. Be-
fore data analysis took place, the statistical analysis plan
for the TransATAC study was approved by the Long-term
Anastrozole vs Tamoxifen Treatment Effects committee
and that for the POLAR study was approved by the RMH
Committee for Clinical Research, and these plans are
described in Additional file 1: Methods. All statistical tests
were two-sided.
Results
We performed the following steps in our study. We used
publicly available microarray data to generate lists of prog-
nostic genes to be analysed in the TransATAC cohort. We
developed early, late and 10-year prognostic signatures in
a training data set (two-thirds of TransATAC) while
setting aside a test set (one-third of TransATAC) so that
the performance of the newly trained signatures could be
evaluated. This internal validation included comparison
with commercial signatures of BCI, Oncotype DX RS,
PAM50 ROR and IHC4. Finally, we conducted an external
validation in the POLAR case-control sample set.
Candidate gene selection and microarray expression data
analysis
In order to derive time-dependent prognostic signatures,
we shortlisted 585 candidate genes representing prolifera-
tion, oestrogen signalling, immune infiltration and im-
mune signalling. These genes were tested for prognostic
significance in publicly available gene expression sets of
ER+ endocrine therapy-treated breast cancer. A flowchart
illustrating the approach is shown in Fig. 1. Sixty-seven
genes of interest that are part of the PAM50, Oncotype
DX RS, EndoPredict and BCI profilers were also included.
Additional genes likely to be related to benefit from
endocrine therapy were identified from 81 patients by re-
analysing our previously published neoadjuvant endocrine
therapy-treated set of samples [19] (https://www.synap-
se.org/#!Synapse:syn16243). From this dataset, we identi-
fied 164 candidate genes by examining correlation of
individual gene expression from untreated biopsies with
change in the following after 2 weeks of AI treatment: (1)
Ki-67, (2) proliferation-associated gene cluster, (3)
oestrogen-associated gene cluster, and (4) expression of
the modified version of the Global Index of Dependence
on Estrogen [20] genes. An additional 354 genes were
selected on the basis of literature searches. Genes from
published gene modules of the proliferation-associated
gene cluster, oestrogen-associated gene cluster and inflam-
matory response signature [19], the tumour invasion/me-
tastasis module (PLAU) [21] and IGG-14 module
(immunoglobulin-gamma) [22] were also included. The
complete list of candidate genes and the reason for their
inclusion are detailed in Additional file 2: Table S1.
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Seven hundred forty-seven samples from the microarray
expression dataset were compiled from four publicly avail-
able breast cancer cohorts to investigate the relationship
between genes and outcome (Additional file 2: Table S2)
[5, 23–25]. Expression data were available for 454 genes
(Additional file 2: Table S3). We performed univariate Cox
proportional hazards regression analyses for early, late and
10-year follow-up periods using RFS and DMFS as end-
points, respectively (six analyses), that identified 212 genes
that were significant at p < 0.01 in any of the analyses
(Additional file 2: Table S4). Genes significantly prognostic
in a particular time period were taken forward for
multivariable analyses performed by Cox proportional
hazards regression with DMFS and RFS as endpoints, re-
spectively, in the early, late and 10-year follow-up settings
(six analyses). This resulted in 88 genes being selected in
the models (Additional file 2: Table S5), of which 17 genes
were removed owing to high correlation of expression
with other candidates already selected (Additional file 2:
Table S6). An additional 29 genes were added that
included candidates without probes available in the micro-
array expression data analyses, some recently emerging
candidates and also seven reference genes (Additional
file 2: Table S7).
Fig. 1 Flowchart of gene signature derivation in the microarray and TransATAC cohorts. QC Quality control, ATAC Arimidex, Tamoxifen, Alone or
in Combination
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Expression profiling and signature building in TransATAC
Sample availability in TransATAC is shown in Fig. 2a.
Expression data for the 100 selected genes (including
housekeeping genes) (Additional file 2: Table S9) were
obtained for 948 patient samples in TransATAC using the
NanoString nCounter. We assessed the prognostic value
of these molecular variables in TransATAC for early, late
and 10-year time periods for RFS. Sixty-three genes were
statistically significant in at least one of the time windows
assessed (Additional file 2: Table S7, Additional file 3:
Figure S1). We found different prognostic properties
between early and late periods for 20 genes. Six genes
were prognostic early but not in the late period (CD79,
IL6ST, LRRC48, MPZL1, PGR and PIGV), and 14 genes
were not significantly prognostic early but gained prog-
nostic significance in the late setting (ANP32E, ANXA1,
CTSL2, EPB41L2, ESR1, FOXA1, ICOS, IL17RB, MMP9,
MYCBP2, NR2F1, PDZK1, SLAMF8 and TCF7L2).
The TransATAC cohort was then randomly split into
two-thirds (n = 634) training and one-third (n = 314)
validation sets while ensuring that the recurrence rate
was similar in the two subgroups. Demographics for the
training, validation and overall cohorts are presented in
Table 1. We aimed to select prognostic variables inde-
pendent of clinicopathological features that are com-
monly used for prognosis. To achieve this, on top of the
63 statistically significant genes in univariate analyses,
CTS was also entered into multivariable selections for
early, late and 10-year time-periods, respectively. Elastic
net penalised Cox regression with leave-one-out
cross-validation was used for feature selection in the
TransATAC training set. CTS was selected in all three
signatures in addition to 18 genes in the 10-year, 16
genes in the early, and 15 genes in the late follow-up
analyses. The variables and their coefficients derived
from the elastic net models are listed in Table 2. CTS
had the highest coefficient in each of the time periods.
Comparison of time period-optimised prognostic
signatures in TransATAC validation set
TransATAC was used to validate and compare the prog-
nostic information of the three time period-dependent
a b
Fig. 2 Consolidated Standards of Reporting Trials (CONSORT) diagram of the availability of samples for analysis from (a) the ATAC trial and (b) the
POLAR collection of samples. POLAR Molecular Predictors Of early versus LAte Recurrence in ER-positive breast cancer, ATAC Arimidex, Tamoxifen,
Alone or in Combination, ER Oestrogen receptor, PgR Progesterone receptor, RMH Royal Marsden Hospital, LUH Lund University Hospital, ET Endocrine
therapy, HER2 Human epidermal growth factor receptor 2
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Table 1 Demographics of TransATAC and POLAR cohorts
TransATAC POLAR
POLAR RMH POLAR LUH Total POLAR (RMH + LUH)
Patient group Training Validation Total Cases Controls Total Cases Controls Total Cases Controls Total
Number of
patients
634 314 948 114 105 219 133 70 203 247 175 422
Age at diagnosis,
yearsa
Mean, years 64 65 65 56 58 57 62 60 61 59 58 59
Median, years 64 64 64 54 58 56 61 58 61 58 58 58
Range, years 48–89 47–86 47–89 29–93 28–88 28–93 35–100 35–87 35–100 29–100 28–88 28–100
Tumour size
< 2 cm 427 (67%) 207 (66%) 634 (67%) 40 (35%) 43 (41%) 83 (38%) 40 (30%) 27 (39%) 67 (33%) 80 (32%) 70 (40%) 150 (36%)
2–5 cm 194 (31%) 101 (32%) 295 (31%) 63 (55%) 54 (51%) 117 (53%) 89 (67%) 40 (57%) 129 (64%) 152 (62%) 94 (54%) 246 (58%)
> 5 cm 13 (2%) 6 (2%) 19 (2%) 11 (10%) 8 (8%) 19 (9%) 4 (3%) 3 (4%) 7 (3%) 15 (6%) 11 (6%) 26 (6%)
Grade
1 177 (28%) 88 (28%) 265 (28%) 12 (11%) 14 (13%) 26 (12%) 9 (7%) 11 (16%) 20 (10%) 21 (9%) 25 (14%) 46 (11%)
2 368 (58%) 169 (54%) 537 (57%) 48 (42%) 52 (50%) 100 (46%) 72 (54%) 35 (50%) 107 (53%) 120 (49%) 87 (50%) 207 (49%)
3 89 (14%) 57 (18%) 146 (15%) 54 (47%) 39 (37%) 93 (42%) 52 (39%) 24 (34%) 76 (37%) 106 (43%) 63 (36%) 169 (40%)
Histological
subtype
IDC 492 (78%) 230 (73%) 722 (76%) 80 (70%) 75 (71%) 155 (71%) 104 (78%) 55 (79%) 159 (78%) 184 (74%) 130 (74%) 314 (74%)
ILC 86 (14%) 60 (19%) 146 (15%) 22 (19%) 18 (17%) 40 (18%) 27 (20%) 15 (21%) 42 (21%) 49 (20%) 33 (19%) 82 (19%)
Other 56 (9%) 24 (8%) 80 (8%) 12 (11%) 12 (11%) 24 (11%) 2 (2%) 0 (0%) 2 (1%) 14 (6%) 12 (7%) 26 (6%)
Nodal status
Node
negative
441 (70%) 224 (71%) 665 (70%) 60 (53%) 56 (53%) 116 (53%) 42 (32%) 29 (41%) 71 (35%) 102 (41%) 85 (49%) 187 (44%)
1–3 positive
nodes
136 (22%) 63 (20%) 199 (21%) 25 (22%) 34 (32%) 59 (27%) 54 (41%) 31 (44%) 85 (42%) 79 (32%) 65 (37%) 144 (34%)
4 or more
nodes
57 (9%) 27 (9%) 84 (9%) 29 (25%) 15 (14%) 44 (20%) 37 (28%) 10 (14%) 47 (23%) 66 (27%) 25 (14%) 91 (22%)
PgR
Negative 114 (18%) 46 (15%) 160 (17%) 5 (4%) 7 (7%) 12 (5%) 25 (19%) 9 (13%) 34 (17%) 30 (%) 16 (%) 46 (11%)
Positive 513 (81%) 268 (85%) 781 (82%) 20 (18%) 23 (22%) 43 (20%) 102 (77%) 56 (80%) 158 (78%) 122 (%) 79 (%) 201 (48%)
Unknown 7 (1%) – 7 (1%) 89 (78%) 75 (71%) 164 (75%) 6 (5%) 5 (7%) 11 (5%) 95 (%) 80 (%) 175 (41%)
NPI categorya
≤ 3.4 298 (47%) 140 (45%) 438 (46%) 25 (22%) 26 (25%) 51 (23%) 15 (11%) 13 (19%) 28 (14%) 40 (16%) 39 (22%) 79 (19%)
3.4–5.4 281 (44%) 147 (47%) 428 (45%) 49 (43%) 50 (48%) 99 (45%) 77 (58%) 42 (60%) 119 (59%) 126 (51%) 92 (53%) 218 (52%)
> 5.4 55 (9%) 27 (9%) 82 (9%) 40 (35%) 29 (28%) 69 (32%) 41 (31%) 15 (21%) 56 (28%) 81 (33%) 44 (25%) 125 (30%)
Endocrine
therapya
Tamoxifen
only
301 (47%) 163 (52%) 464 (49%) 80 (70%) 72 (69%) 152 (69%) 96 (72%) 50 (71%) 146 (72%) 176 (71%) 122 (70%) 298 (71%)
AI 333 (53%) 151 (48%) 484 (51%) 34 (30%) 33 (31%) 67 (31%) 37 (28%) 20 (29%) 57 (28%) 71 (29%) 53 (30%) 124 (29%)
Chemotherapya
No 634 (100%) 314 (100%) 948 (100%) 54 (47%) 49 (47%) 103 (47%) 94 (71%) 55 (79%) 149 (73%) 148 (60%) 104 (59%) 252 (60%)
Yes 0 0 0 60 (53%) 56 (53%) 116 (53%) 39 (29%) 15 (21%) 54 (27%) 99 (40%) 71 (41%) 170 (40%)
Abbreviations: AI Aromatase inhibitor, IDC Invasive ductal carcinoma, ILC Invasive lobular carcinoma, PgR Progesterone receptor, NPI Nottingham
Prognostic Index, RMH Royal Marsden Hospital, LUH Lund University Hospital, POLAR Molecular Predictors Of early versus LAte Recurrence in ER+
breast cancer
a Denotes matching criteria in POLAR
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signatures (Table 3). In the 0–10-year follow-up period,
all three newly derived signatures were significantly
prognostic, with the late signature being significantly less
informative than the 10-year signature (10-year signature
likelihood ratio chi-square test [LRχ2] = 28.0; early signa-
ture LRχ2 = 33.4; late signature LRχ2 = 18.1). In the 0–
5-year period, the 10-year signature and early signature
were equally prognostic and significantly more than the
late signature (LRχ2 for 10-year signature = 14.1; LRχ2
for early signature = 14.9; LRχ2 for late signature = 8.9).
In the late setting, the early signature was the most
prognostic, followed by the 10-year and late signatures
(LRχ2 for 10-year signature = 13.9; LRχ2 for early signa-
ture = 18.6; LRχ2 for late signature = 9.3). CTS was
strongly prognostic in all three time periods (CTS 0–
10-year LRχ2 = 48.7; CTS 0–5-year LRχ2 = 29; CTS 5–
10-year LRχ2 = 19.8).
For the 0–10-year period, all three signatures added
statistically significant prognostic information beyond that
of the CTS (ΔLRχ2 for 10-year signature = 7.9; ΔLRχ2 for
early signature = 10.3; ΔLRχ2 for late signature = 4.3). In
the 0–5-year period none of the signatures added signifi-
cant prognostic information to CTS. However, in the 5–
10-year period, the 10-year and early signatures added
statistically significant prognostic information to CTS
(10-year signature ΔLRχ2 = 4.8; early signature ΔLRχ2 =
8.0; late signature ΔLRχ2 = 2.7).
Given that the early and the late signatures were not
statistically significantly more prognostic than the 10-year
signature in the respective periods they were optimised
for, we rejected our primary hypothesis that signatures
optimised separately for the early and the late follow-up
periods, respectively, are more prognostic than a 10-year
signature, but we proceeded to assess the validity of the
18-gene, 10-year signature in an independent cohort and
to compare its performance with that of commercial
signatures.
Signature test of 10-year validity in POLAR cohort
A matched case-control set of samples was compiled from
RMH and Lund University Hospital archives (POLAR) to
validate the 10-year signature (Fig. 2b, Table 1). Our aims
were to test the validity the 10-year signature in an
endocrine therapy-only cohort similar to the training set
and also to explore if the prognostic property (if any)
extends to a higher-risk, chemotherapy-treated popula-
tion. The latter cohort was of interest in the 5–10-year
period because of the potential for its use in selecting
patients for extended adjuvant endocrine therapy.
Despite having matched cases and controls on NPI
category, the CTS was still higher in cases than in control
subjects: 201.9 ± 98 (SD) vs. 170.8 ± 87.6 (p = 0.0009),
respectively. In a univariate analysis, CTS had an OR of
1.004 (95% CI, 1.001–1.006) for a one-unit increase. We
assessed a multivariable model with CTS with and the
10-year signature, and both were found to be statistically
significant: 10-year signature OR= 1.851 (95% CI, 1.194–
2.868), p = 0.006; CTS OR= 1.003 (1.001–1.005), p = 0.012.
We also assessed whether the 10-year signature added
significant prognostic information above CTS alone using
LR tests (Table 4, Additional file 4: Table S10). In the over-
all POLAR cohort (n = 422), CTS was prognostic across
10 years and in the early follow-up period (CTS 0–10-year
period LRχ2 = 11.23; 0–5-year period LRχ2 = 22.09), but
not in the 5–10-year period. The 10-year signature was
prognostic in all three follow-up periods and contributed
to CTS with significant prognostic information in the
10-year and early periods (0–10-year period ΔLRχ2, CTS
Table 2 Variables and corresponding beta-coefficients of the
time-dependent 10-year, early and late signatures
Variable 10-Year signature Early signature Late signature
ALDH1A1 −0.194
ANP32E 0.143 0.010 0.083
CRABP2 0.084 0.207
CXCL12 −0.183
CXCR4 0.142 0.056
EGFR −0.030
ELF5 −0.046 −0.001
FGF2 −0.178 −0.232
IGF1 −0.029 −0.017
IGJ −0.086 −0.037 −0.030
IL6ST −0.044
LINC00341 − 0.463 − 0.362 − 0.392
LRRC48 − 0.104
MMP9 0.043 0.064
MPZL1 0.276 0.066 0.043
NUSAP1 0.088 0.065
PBX1 0.159 0.375
PDZK1 −0.011 −0.063
PGR − 0.073
PRC1 0.019
RGL1 −0.429 − 0.166 − 0.161
RRM2 0.077 0.124
SFRP1 −0.017 −0.278
STC2 −0.087 −0.068
TNF −0.029 −0.026
ZEB2 −0.138
CTS 0.514 0.409 0.516
Positive coefficients are associated with higher recurrence risk; negative
coefficients are associated with lower recurrence risk. Beta-coefficients were
normalised by dividing them by the SD of the respective variables in the
training population
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+ 10-year signature vs. CTS = 7.74; 0–5-year period
ΔLRχ2, CTS + 10-year signature vs. CTS = 7.59), but not
in the 5–10-year period. Both CTS and the 10-year signa-
ture were marginally more informative across the 10 years
in the chemotherapy-treated POLAR cohort than in the
endocrine therapy-only population, despite the latter hav-
ing more patients and events (patients, n = 170 vs. n = 252;
events, 99 vs. 148). Additionally, the 10-year signature
added significantly more prognostic information to CTS
in the chemotherapy-treated group (ΔLRχ2: CTS + 10-year
signature vs. CTS = 6.71) than among those receiving
endocrine therapy only (ΔLRχ2, CTS + 10-year signature
vs. CTS = 2.47).
Prognostic properties of the 18 individual genes consti-
tuting the 10-year signature were assessed in POLAR and
compared with data obtained in TransATAC. In POLAR,
only 8 of the 18 genes were significantly prognostic at the
univariate level (Fig. 3), but all genes except tumour
Table 3 Statistical analysis of TransATAC validation cohort
Score No. of
patients
(relapses)
Univariate comparisons Multivariable comparisons
CTS + signature vs CTS CTS + signature
LRχ2 p Value HR (95% CI) P diff C-index (SE) ΔLRχ2 p Value HR (95% CI) P diff C-index (SE)
0–10 years
CTS 314 (59) 48.7 < 0.001 2.16 (1.79–2.62) – 0.674 (0.018) – – – – –
10-Year signature 28 < 0.001 1.98 (1.54–2.55) Reference 0.671 (0.026) 7.9 0.005 1.49 (1.13–1.96) Reference 0.709 (0.021)
Early signature 33.4 < 0.001 2.06 (1.62–2.61) 0.334 0.678 (0.024) 10.3 0.001 1.55 (1.19–2.02) 0.48 0.711 (0.020)
Late signature 18.1 < 0.001 1.72 (1.34–2.20) 0.000 0.642 0(.029) 4.3 0.037 1.33 (1.02–1.74) 0.004 0.700 (0.022)
0–5 years
CTS 314 (26) 29 < 0.001 2.04 (1.53–2.74) – 0.679 (0.023) – – – – –
10-Year signature 14.1 < 0.001 2.05 (1.41–2.98) 0.833 0.678 (0.037) 3.2 0.073 1.46 (0.97–2.19) 0.77 0.712 (0.029)
Early signature 14.9 < 0.001 2.00 (1.42–2.81) Reference 0.672 (0.035) 2.8 0.096 1.40 (0.95–2.06) Reference 0.705 (0.028)
Late signature 8.9 0.003 1.77 (1.22–2.57) 0.138 0.648 (0.042) 1.7 0.19 1.31 (0.87–1.97) 0.65 0.705 (0.031)
5–10 years
CTS 270 (33) 19.8 < 0.001 1.84 (1.33–2.54) – 0.657 (0.026) – – – – –
10-Year signature 13.9 < 0.001 1.93 (1.37–2.72) 0.027 0.663 (0.036) 4.8 0.028 1.53 (1.05–2.22) 0.14 0.696 (0.030)
Early signature 18.6 < 0.001 2.11 (1.52–2.94) 0.091 0.681 (0.032) 8 0.005 1.70 (1.19–2.43) 0.14 0.708 (0.028)
Late signature 9.3 0.002 1.68 (1.21–2.34) Reference 0.636 (0.038) 2.7 0.099 1.36 (0.95–1.94) Reference 0.686 (0.031)
CTS Clinical Treatment Score, LR Likelihood ratio
Both univariate and multivariable analyses are presented for years 0–10, years 0–5, and years 5–10 separately. Likelihood ratio test based on Cox
proportional hazards models for univariate and multivariable analyses. Differences in likelihood ratio values (ΔLRχ2) were used. CTS was used as a
covariate in the multivariable regressions. For each score, HRs per SD change are presented
Table 4 Statistical analysis of three groups of POLAR validation set for 0–10 years of follow-up
All POLAR patients Chemotherapy-treated Chemotherapy-naive
0–10 Years
No. of patients (relapses) n = 422 (247) n = 170 (99) n = 252 (148)
Univariate CTS LRχ2 11.23 7.75 6.1
P < 0.001 0.005 0.014
C-index (SE) 0.594 (0.028) 0.623 (0.044) 0.590 (0.036)
10-Year signature LRχ2 12.44 7.73 5.39
P < 0.004 0.005 0.020
C-index (SE) 0.593 (0.028) 0.619 (0.044) 0.578 (0.037)
Multivariable comparisons CTS + 10-year signature vs CTS ΔLRχ2 7.74 6.71 2.47
P 0.005 0.001 0.116
CTS + 10-year signature C-index (SE) 0.617 (0.028) 0.669 (0.042) 0.598 (0.036)
Abbreviations: POLAR Molecular Predictors Of early versus LAte Recurrence in ER-positive breast cancer, CTS Clinical Treatment Score, LR Likelihood ratio, SE
standard error
Both univariate and multivariable analyses are presented for years 0–10, years 0–5, and years 5–10 separately. Likelihood ratio test based on Cox proportional
hazards models for univariate and multivariable analyses. Differences in likelihood ratio values (ΔLRχ2) were used. CTS was used as a covariate in the multivariable regressions
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necrosis factor-alpha (TNF) showed the same prognostic
direction both in TransATAC and in POLAR.
Comparison of the 10-year signature with CTS, RS, PAM50
ROR, BCI and IHC4 in TransATAC
We have previously published data on the prognostic
performance of CTS, RS, PAM50 ROR, BCI and IHC4
in TransATAC [6, 15, 18, 26]; data for all scores were
available for 271 patients in the validation cohort. We
assessed their prognostic information for 10 years after
surgery using any recurrence and distant recurrence as
endpoints, respectively, and compared them with the
newly developed 10-year signature (Table 5). For both
any and distant recurrence, the BCI provided the most
added information beyond the CTS in this set (any
recurrence, CTS LRχ2 = 37.4; BCI ΔLRχ2 = 9.5; distant
recurrence, CTS LRχ2 = 46.7; BCI ΔLRχ2 = 14.5, respect-
ively). The novel 10-year signature performed similarly
to the other three scores in this respect.
Discussion
We developed novel time-specific prognostic signatures for
early, late and 10-year follow-up periods for ER+/HER2−
patients treated with endocrine therapy alone to allow us to
test the hypothesis that sequentially applying early and late
signatures could be more prognostic for risk of relapse than
a single newly developed 10-year signature. This hypothesis
was based largely on our observation that the performance
of some components in many of the commercially available
signatures varied between these time periods. For example,
we found that ESR1 and the oestrogen module overall in
the RS was less prognostic in years 5–10 than in years 0–5
[8]. Analogous findings were reported by Bianchini et al.
[9]. Very recently, the Early Breast Cancer Trialists’ Collab-
orative Group (EBCTCG) published data on clinicopatho-
logical and limited immunohistochemical data on over
60,000 women who were treated with 5 years of endocrine
therapy [27]. Although progesterone receptor showed
strong prognostic performance in years 0–5, it showed no
significant relationship with prognosis thereafter. These
data on markers associated with hormone responsiveness
support the contention, but by no means prove, that
cessation of endocrine treatment at 5 years may lead to
increased recurrence risk in more hormonally responsive
tumours. We therefore included in our assessment genes
that we and others have found to be associated with the
anti-proliferative response of primary ER+ breast cancer to
oestrogen deprivation. Our work involved a discovery set of
747 samples; training and test sets of 634 and 314 Trans-
ATAC samples, respectively; and independent case-control
series from 1449 eligible samples. As such, this was one of
the largest original gene expression analyses undertaken for
evaluating prognosis in ER+ breast cancer.
Of the 92 genes selected from microarray data and
assessed in univariate analyses in TransATAC, we found
63 to be significantly prognostic (p < 0.05) in any of the
three time periods, which is considerably more than
expected by chance after allowing for multiple testing
Fig. 3 HRs and ORs for the 10-year signature genes in TransATAC and POLAR, respectively. POLAR Molecular Predictors Of early versus LAte
Recurrence in ER-positive breast cancer, ATAC Arimidex, Tamoxifen, Alone or in Combination
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errors. For most genes, the same prognostic pattern was
observed for early and late periods, however we observed
some possibly different prognostic properties for 20 genes.
Notably, consistent with the above arguments, higher
levels of ESR1 and its pioneer factor FOXA1 showed a
shift at 5 years to be associated with worse prognosis
beyond 5 years, but surprisingly over the 10-year period,
the two genes were associated with poor prognosis. The
complementary role whereby upon stimulus ER binding
to chromatin is dependent on the presence of FOXA1 is
well established [28]. In our dataset, FOXA1 and ESR1
correlated highly (Pearson’s R = 0.65); the possibility that
increased expression of one or both may put patients at
increased risk of late relapse merits further investigation,
particularly with regard to whether the genes also identify
patients who benefit from extended adjuvant therapy.
The optimised time-dependent signatures derived in the
TransATAC training set were rather similar to one another
in makeup. All genes in the 10-year signature featured in
either (or both) of the early and late signatures with their
coefficients being in the same direction. The early and late
signatures had five and three variables, respectively, not
present in the 10-year signature, suggesting that the early
and late signatures may not have captured time-specific
features or that such time-specific features that exist exert a
minor modulatory influence on the overall prognosis over
10 years. It is notable that CTS was consistently the most
prognostic variable in the three time-dependent models
and that its contribution was similar in both early and late
recurrence. This is consistent with the data of the EBCTCG
that classical clinicopathological features retain their strong
prognostic influence beyond 5 years [27].
Given that the 10-year signature captured prognostic
features of both early and late events, it is perhaps not
surprising that no improvement was seen in the use of
early and late signatures compared with the overall
10-year signature that led to the rejection of our hypoth-
esis. Also, it should be noted that splitting of the 0–
10-year time period into 0–5- and 5–10-year periods
markedly reduces the power to detect prognostic contri-
butions. At least a contributory factor for the lack of im-
provement may be the dominance of proliferation-related
genes in our and other signatures. As shown in our earlier
analysis of the RS, each of the individual proliferation
genes and the integrated module are equally prognostic
before and after 5 years [8]. Notably, this is also supported
by the observation by the EBCTCG that Ki-67 was equally
prognostic before and after 5 years in their overview ana-
lysis of late recurrence [27].
The 10-year signature was nonetheless validated in
the POLAR sample set and provided significant
prognostic information in both chemotherapy-naive
and chemotherapy-treated cohorts. Moreover, it added
independent prognostic information beyond that of
CTS in the POLAR cohort. Comparison of the informa-
tion provided by each gene showed that 8 of the 18 genes
Table 5 Statistical analysis for all and distant recurrences in the TransATAC validation cohort
Score Univariate Multivariable comparisons
CTS + signature vs CTS CTS + signature
LRχ2 p Value HR (95% CI) C-index (SE) ΔLRχ2 p Value HR (95% CI) C-index (SE)
All recurrences (n = 271, AR = 55)
CTS 37.4 < 0.001 1.94 (1.57–2.40) 0.664 (0.020) – – – –
10-Year signature 20.7 < 0.001 1.85 (1.42–2.41) 0.657 (0.029) 5.7 0.017 1.42 (1.07–1.89) 0.695 (0.023)
BCI 25.0 < 0.001 2.07 (1.54–2.77) 0.679 (0.029) 9.5 0.002 1.62 (1.19–2.21) 0.711 (0.024)
RS 11.1 < 0.001 1.52 (1.21–1.91) 0.607 (0.027) 5.8 0.016 1.35 (1.07–1.71) 0.683 (0.021)
ROR 18.3 < 0.001 1.77 (1.36–2.31) 0.650 (0.030) 6.0 0.014 1.42 (1.07–1.87) 0.700 (0.024)
IHC4 14.4 < 0.001 1.63 (1.28–2.10) 0.629 (0.029) 7.5 0.006 1.46 (1.12–1.91) 0.696 (0.023)
Distant recurrences (n = 271, DR = 41)
CTS 46.7 < 0.001 2.25 (1.79–2.82) 0.689 (0.019) – – – –
10-Year signature 26.4 < 0.001 2.24 (1.64–3.06) 0.694 (0.029) 8.5 0.004 1.65 (1.18–2.30) 0.733 (0.023)
BCI 34.0 < 0.001 2.71 (1.91–3.84) 0.726 (0.028) 14.5 < 0.001 2.03 (1.40–2.95) 0.754 (0.023)
RS 10.7 < 0.001 1.58 (1.23–2.03) 0.616 (0.029) 5.1 0.024 1.38 (1.06–1.79) 0.707 (0.020)
ROR 21.3 < 0.001 2.05 (1.50–2.79) 0.680 (0.031) 7.5 0.006 1.58 (1.14–2.21) 0.736 (0.024)
IHC4 17.9 < 0.001 1.87 (1.41–2.49) 0.658 (0.031) 9.8 0.002 1.68 (1.22–2.31) 0.731 (0.023)
Abbreviations: AR All recurrences, DR Distant recurrences, CTS Clinical Treatment Score, BCI Breast Cancer Index, RS Recurrence score, ROR Risk of recurrence, LR
Likelihood ratio
Both univariate and multivariable analyses are presented. For each score, HRs per SD change are presented. Likelihood ratio test based on Cox proportional
hazards models for univariate and multivariable analyses. Differences in likelihood ratio values (ΔLRχ2) were used. CTS was used as a covariate in the
multivariable regressions
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were significantly prognostic at univariate level in POLAR
(4 genes at P < 0.05, 2 genes at P < 0.01 and 3 genes at P <
0.001). TNF showed an opposite prognostic direction in
training and validation sets, thus weakening the perform-
ance of the signature in POLAR. TNF is a versatile
pro-inflammatory cytokine that has both pro- and
anti-tumour activities promoting lymphocytic infiltration
and activating the nuclear factor-κB, c-Jun N-terminal
kinase and mitogen-activated protein kinase pathways,
and it is capable of inducing apoptosis through TNF
receptors 1 and 2 [29]. It may be that the inclusion of
higher-risk, chemotherapy-treated patients in POLAR
contributed to the difference in TNF’s prognostic pattern;
further investigation is needed to explain the relationship
of TNF and risk of relapse in these cohorts.
The 10-year signature was compared with established
prognostic signatures in the TransATAC validation set.
Importantly, the 10-year signature was developed for the
endpoint of any recurrence contrary to the endpoint of
distant recurrence used in the development of RS,
PAM50, ROR, BCI and IHC4. In univariate assessments,
BCI and the 10-year signatures were the most informative
for both all and distant recurrence. When added to CTS,
all signatures assessed provided similar amounts of infor-
mation, with CTS + BCI being the most informative for
distant recurrence. This new signature did not outperform
the established signatures, even though it was based on a
large and wide-ranging analysis of both established prog-
nostic genes and novel genes with a clear rationale for
inclusion. Larger studies may be needed to fully optimise
novel prognostic signatures with improved prognostic
information, however the data from our studies indicate
that the gain is unlikely to be large. Other approaches that
assess response to treatment or integrate mutational and
DNA copy number profiles or by the use of circulating
tumour DNA are likely to be more fruitful.
The results presented here support the mounting
evidence that better risk estimation can be achieved by
combining molecular profilers with clinicopathological
factors. For the three time-dependent signatures derived
in TransATAC, CTS was the most prognostic in all three
time-dependent signatures and provided more prognostic
information than RS, ROR, BCI and IHC4, respectively.
Additionally, all profilers added significant prognostic in-
formation to CTS, leading to combined signatures being
significantly more informative. There is emerging evidence
for genetic differences affecting outcome amongst various
racial groups [30]. Although this is an important question
with practical consequences, the cohort presented here
was > 99% Caucasian and did not provide us with the
opportunity to examine within TransATAC.
Our study has strengths and limitations. An advantage
was that a large discovery cohort of 634 samples was used
for signature training. All tumours were ER+/HER2− from
post-menopausal patients who had received 5 years of
endocrine therapy without chemotherapy. This was a
homogeneous group of breast cancers, which reduced
confounding factors such as tumour subtype and differing
treatment lengths and types. Data for the clinical prognos-
tic tests were obtained by the same methods as set out by
the tests’ developers. The same batch of RNA was used
for the newly developed signatures presented here and for
the clinical prognostic tests used in the comparisons,
reducing intra-sample variation. The clinical data were
derived from a registration standard trial with comprehen-
sive follow-up over 10 years. Limitations include that the
candidate gene selection based on microarray data and
associated clinical information from multiple studies did
not allow the assessment of candidates by taking multiple
clinical variables into account; this may have limited the
performance of derived signatures that ultimately included
CTS as a variable. Also, CTS, IHC4 and the 10-year
signature were derived in TransATAC; therefore, their
performance in the comparisons was slightly overesti-
mated compared with what we would see in independent
cohorts. Finally, although this study was relatively large
compared with others, the splitting of the data into early
and late signatures decreased the statistical power for
comparisons within those time periods. The approach we
have taken is likely to have somewhat overfitted the
10-year signature to the TransATAC population. An alter-
native approach for the derivation and validation of the
10-year signature would have been to fit the signature to
the whole of the TransATAC cohort and validate it in the
POLAR cohort. However, the approach we took allowed
the comparison of the 10-year signature with commer-
cially available signatures in the TransATAC test set. Had
the 10-year signature not at least matched these, it would
not have been worth proceeding further.
Conclusions
In summary, we found that early and late signatures are
unlikely to be more informative for predicting relapse than
a single signature optimised for 10 years. Larger studies
may be needed to fully optimise novel gene expression
signatures for prognosis in endocrine-treated ER+ patients
with breast cancer, however a substantial improvement in
performance is unlikely.
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